EAST HANOVER, N.J., March 28, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with ...

What Is Pluvicto and How Does It Work? The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat adults with a specific type of advanced prostate cancer. It is used for prostate ...

Prostate cancer treatment has undergone a remarkable transformation over the past decade, with the integration of androgen ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any ...

Novartis has pushed its second radioligand therapy over the FDA finish line, and the Swiss pharma has more than $2 billion in peak sales expectation linked to the new launch. Wednesday, the FDA ...

What does the new Pluvicto approval mean for prostate cancer? Here is who may qualify, how it works, benefits, side effects and treatment details.

While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate ...

A recently FDA-approved drug offers patients with metastatic castration-resistant prostate cancer a newer treatment that improves survival, but is not curative of the disease, which means that more ...

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...

Consistent with our focus on leading-edge innovation, ATNM-400 is highly novel given it is a non-PSMA target receptor, which is highly expressed in mCRPC, and as we have presented at AACR, continues ...

The FDA decision announced Wednesday covers adults whose cancer is positive for prostate-specific membrane antigen (PSMA), a protein abundant on the surface of prostate cancer cells. The Novartis ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...